63071-09-0

Basic information

• Product Name: 2-HYDROXYMETHYL-3-METHYLPYRIDINE
• Synonyms: 2-HYDROXYMETHYL-3-METHYLPYRIDINE;(3-METHYLPYRIDINE-2-YL)METHANOL;3-METHYL-2-PYRIDINEMETHANOL;(3-methylpyridin-2-yl)methanol;2-Pyridinemethanol, 3-methyl-
• CAS NO: 63071-09-0
• Molecular Formula: C₇H₉NO
• Molecular Weight: 123.15
• Product Categories: pharmacetical
• Mol File: 63071-09-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 102 °C
• Boiling Point: 236.8 °C at 760 mmHg
• Flash Point: 97 °C
• Appearance: /
• Density: 1.092 g/cm³
• Vapor Pressure: 0.0255mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform (Sparingly), Ethyl Acetate (Slightly, Sonicated)
• PKA: 13.51±0.10(Predicted)
• CAS DataBase Reference: 2-HYDROXYMETHYL-3-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-HYDROXYMETHYL-3-METHYLPYRIDINE(63071-09-0)
• EPA Substance Registry System: 2-HYDROXYMETHYL-3-METHYLPYRIDINE(63071-09-0)

Safety Data

• Hazardous Substances Data: 63071-09-0(Hazardous Substances Data)

Usage

Description

2-HYDROXYMETHYL-3-METHYLPYRIDINE, also known as (3-Methylpyridin-2-yl)methanol, is an organic compound with a unique chemical structure that features a hydroxymethyl group and a methylpyridine moiety. 2-HYDROXYMETHYL-3-METHYLPYRIDINE has attracted attention for its potential applications in various fields due to its specific interactions and properties.

Uses

Used in Pharmaceutical Industry:
2-HYDROXYMETHYL-3-METHYLPYRIDINE is used as a therapeutic agent for selectively suppressing MLL rearranged leukemia cells. 2-HYDROXYMETHYL-3-METHYLPYRIDINE targets and disrupts the MLL-1-WDR5 protein-protein interaction, which is a critical pathway in the development and progression of certain types of leukemia. By inhibiting this interaction, 2-HYDROXYMETHYL-3-METHYLPYRIDINE can potentially offer a novel treatment strategy for patients with MLL rearranged leukemia.

InChI:InChI=1/C7H9NO/c1-6-3-2-4-8-7(6)5-9/h2-4,9H,5H2,1H3

Upstream product

• 583-61-9 2,3-Lutidine 
• 22710-07-2 2,3-dimethylpyridine 1-oxide 
• 407-25-0 trifluoroacetic anhydride 
• 52814-41-2 2-(acetoxymethyl)-3-methylpyridine 

Downstream Products

• 4377-43-9 2-chloromethyl-3-methyl-pyridine 
• 101870-40-0 (E)-3-methylpicolinaldehyde oxime 
• 927911-32-8 3-(2-fluorobenzyloxy)-5-((3-methylpyridin-2-yl)methoxy)benzaldehyde 
• 260395-28-6 N-benzyl-N,N'N'-tris(3-methylpyridin-2-ylmethyl)ethylene-1,2-diamine 
• 4370-22-3 2-chloromethyl 3-methyl pyridine hydrochloride 
• 55589-47-4 3-methylpyridine-2-carboxaldehyde 

Relevant articles and documents

Methyl Scanning and Revised Binding Mode of 2-Pralidoxime, an Antidote for Nerve Agent Poisoning

Organophosphorus nerve agents (OPNAs) inhibit acetylcholinesterase (AChE) and, despite the Chemical Weapons Convention arms control treaty, continue to represent a threat to both military personnel and civilians. 2-Pralidoxime (2-PAM) is currently the only therapeutic countermeasure approved by the United States Food and Drug Administration for treating OPNA poisoning. However, 2-PAM is not centrally active due to its hydrophilicity and resulting poor blood-brain barrier permeability; hence, these deficiencies warrant the development of more hydrophobic analogs. Specifically, gaps exist in previously published structure activity relationship (SAR) studies for 2-PAM, thereby making it difficult to rationally design novel analogs that are concomitantly more permeable and more efficacious. In this study, we methodically performed a methyl scan on the core pyridinium of 2-PAM to identify ring positions that could tolerate both additional steric bulk and hydrophobicity. Subsequently, SAR-guided molecular docking was used to rationalize hydropathically feasible binding modes for 2-PAM and the reported derivatives. Overall, the data presented herein provide new insights that may facilitate the rational design of more efficacious 2-PAM analogs.

NEUROLOGICALLY-ACTIVE COMPOUNDS

Neurologically-active heterocyclic compounds comprising two fused 6-membered rings with nitrogen atoms at positions 1 and 3, a carboxy group at position 4,and a hydroxy group at position 8, with one ring being aromatic. Processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, and more specifically neurodegenerative conditions such as Alzheimer's disease.

NOVEL NITROGENOUS COMPOUND AND USE THEREOF

A novel nitrogen-containing compound effective against diseases such as HIV viral infectious diseases, rheumatism, and cancerous metastasis. It is a nitrogen-containing compound represented by the following general formula (1). In the formula, A typically represents a group represented by the formula (2) (A1 is hydrogen or an optionally substituted, mono- or polycyclic, heteroaromatic or aromatic ring; G1 is a single bond or a hydrocarbon group represented by the following formula (3) wherein R1, R2, and R3 may be optionally substituted hydrocarbon groups); W is an optionally substituted hydrocarbon group or heterocyclic ring; x is -C(=O)NH-; y is -C(=O)-; and D1 is hydrogen atom, alkyl having a polycyclic aromatic ring, di (substituted alkyl)amine, or alicyclic amine.